EXTON, PA — Lungpacer Medical, Inc. has announced pivotal results from the RESCUE-3 trial, published in the American Journal of Respiratory and Critical Care Medicine, showcasing the groundbreaking benefits of the AeroPace® System for critically ill patients. This international, multi-center, randomized clinical trial demonstrates the system’s ability to accelerate liberation from mechanical ventilation while strengthening diaphragm function.
The trial, conducted across 48 centers in the United States and Europe, enrolled 223 adult patients who had been on mechanical ventilation for at least 96 hours and failed two or more weaning attempts. Results showed that the AeroPace System, combined with standard care, achieved a substantial reduction of an average of three ventilator days, with a 97.5% probability of superiority compared to standard care alone.
“This robust, international trial validates what we’ve long believed – that targeted diaphragm neurostimulation can fundamentally transform outcomes for patients having difficulty weaning from mechanical ventilation,” said Doug Evans, CEO of Lungpacer Medical. “The three-day reduction in ventilator time is highly meaningful for these patients who are struggling each day to breathe again on their own.”
Key Findings from the RESCUE-3 Trial
- Improved Weaning Success: Patients treated with AeroPace displayed a significantly higher rate of successful weaning from mechanical ventilation compared to those receiving standard care, with an adjusted hazard ratio of 1.34.
- Fewer Ventilator Days: AeroPace reduced ventilator time to weaning by 2.5 days and total days on the ventilator to 30 days by 2.8 days.
- Enhanced Diaphragm Strength: Patients achieved a 50% increase in maximum inspiratory pressure, a marker of diaphragm functionality.
- Durable Outcomes: The therapy reduced reintubation by 50%, and fewer patients required tracheostomies within 30 days.
- Safety: AeroPace was well-tolerated, with negligible increases in pain or discomfort reported.
Dr. Martin Dres, one of the lead researchers, emphasized the significance of these findings. “The RESCUE-3 trial represents a pivotal advancement in critical care, offering a novel approach to addressing diaphragm dysfunction in patients requiring prolonged mechanical ventilation. By evaluating the safety and efficacy of the AeroPace System, we aim to provide clinicians with a valuable tool to enhance patient outcomes.”
Dr. Ewan Goligher, another key researcher, added, “Improving outcomes in intensive care has long been challenging. Transvenous diaphragm neurostimulation is a groundbreaking new approach to treating critical respiratory failure. Backed by strong physiological rationale, this therapy represents an exciting and important advancement in intensive care medicine.”
The findings further cement the AeroPace System’s potential to revolutionize critical care by reducing the risks associated with prolonged mechanical ventilation. Published results were also highlighted at the Critical Care Reviews Meeting 2025 in Belfast, Northern Ireland, where the RESCUE-3 trial was globally recognized as one of the most significant contributions to critical care research.
Lungpacer Medical’s technology offers promising solutions for critical care providers, addressing the challenges of prolonged ventilation and enabling improved recovery for critically ill patients worldwide.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.